OTC:PHRRF PharmaTher (PHRRF) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free PHRRF Stock Alerts $0.17 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.17▼$0.1750-Day Range$0.14▼$0.3252-Week Range$0.06▼$0.32Volume262,940 shsAverage Volume541,533 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get PharmaTher alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About PharmaTherPharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS. The company also holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology; and a license agreement with Gesval SA, as well as valuation and exclusive option agreement with Case Western Reserve University for development and commercialization for the intellectual property of ketamine for the treatment of Rett syndrome. PharmaTher Holdings Ltd. was incorporated in 2019 and is headquartered in Toronto, Canada.Read More PHRRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHRRF Stock News HeadlinesApril 18, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 16, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.February 23, 2024 | benzinga.comPharmaTher Holdings Stock (OTC:PHRRF), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comPharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 21, 2024 | globenewswire.comPharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 12, 2024 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineFebruary 12, 2024 | finance.yahoo.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…January 16, 2024 | benzinga.comPharmaTher Holdings Stock (OTC:PHRRF) Dividends: History, Yield and DatesJanuary 10, 2024 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Provides Update for Expected FDA Approval of KetamineJanuary 10, 2024 | msn.comPharmaTher expects FDA to decide on ketamine approval by April 29January 10, 2024 | finance.yahoo.comPharmaTher Provides Update for Expected FDA Approval of KetamineDecember 23, 2023 | seekingalpha.comPHRRF PharmaTher Holdings Ltd.November 11, 2023 | morningstar.comPharmaTher Holdings Ltd PHRRFNovember 11, 2023 | investing.comPharmather Holdings Ltd (PHRM)September 27, 2023 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)September 27, 2023 | finance.yahoo.comPharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)September 17, 2023 | msn.comWith ecstasy a potential PTSD therapy, psychedelic treatments could take offSeptember 6, 2023 | benzinga.comPharmaTher Aims To Mitigate Ketamine Shortage With New FDA ApplicationSeptember 6, 2023 | finance.yahoo.comPharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDAJuly 18, 2023 | benzinga.comPharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical StageJuly 18, 2023 | finanznachrichten.dePharmaDrug Inc.: PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.July 18, 2023 | finance.yahoo.comPharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.July 18, 2023 | finance.yahoo.comPharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo TherapeuticsJune 27, 2023 | benzinga.comKetamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip AssetsJune 27, 2023 | finance.yahoo.comPharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDASee More Headlines Receive PHRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaTher and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:PHRRF CUSIPN/A CIKN/A Webwww.pharmather.com Phone888 846 3171FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Fabio Chianelli (Age 46)Founder, Chairman & CEO Comp: $233.78kMr. Carmelo Marrelli ACIS (Age 53)B.Comm., C.A., CGA, CPA, Chief Financial Officer Comp: $72.14kMr. Andrew Todd (Age 66)Corporate Secretary Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors PHRRF Stock Analysis - Frequently Asked Questions How have PHRRF shares performed in 2024? PharmaTher's stock was trading at $0.24 at the beginning of 2024. Since then, PHRRF stock has decreased by 30.4% and is now trading at $0.1670. View the best growth stocks for 2024 here. How do I buy shares of PharmaTher? Shares of PHRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTC:PHRRF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaTher Holdings Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.